IL311873A - Combination therapy for treating malignancies - Google Patents

Combination therapy for treating malignancies

Info

Publication number
IL311873A
IL311873A IL311873A IL31187324A IL311873A IL 311873 A IL311873 A IL 311873A IL 311873 A IL311873 A IL 311873A IL 31187324 A IL31187324 A IL 31187324A IL 311873 A IL311873 A IL 311873A
Authority
IL
Israel
Prior art keywords
day
subject
administered
mutant idh2
idh2 inhibitor
Prior art date
Application number
IL311873A
Other languages
English (en)
Hebrew (he)
Inventor
Samuel V Agresta
Original Assignee
Agios Pharmaceuticals Inc
Samuel V Agresta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc, Samuel V Agresta filed Critical Agios Pharmaceuticals Inc
Publication of IL311873A publication Critical patent/IL311873A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL311873A 2015-10-15 2016-10-14 Combination therapy for treating malignancies IL311873A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562242256P 2015-10-15 2015-10-15
US201562255194P 2015-11-13 2015-11-13
PCT/US2016/057083 WO2017066599A1 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies

Publications (1)

Publication Number Publication Date
IL311873A true IL311873A (en) 2024-06-01

Family

ID=57208385

Family Applications (2)

Application Number Title Priority Date Filing Date
IL311873A IL311873A (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies
IL258269A IL258269A (en) 2015-10-15 2018-03-21 Combined therapy for the treatment of malignancies

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL258269A IL258269A (en) 2015-10-15 2018-03-21 Combined therapy for the treatment of malignancies

Country Status (15)

Country Link
US (2) US10905692B2 (enExample)
EP (2) EP3362057A1 (enExample)
JP (2) JP2018534288A (enExample)
KR (2) KR20180063125A (enExample)
CN (1) CN108366980A (enExample)
AU (1) AU2016340087C1 (enExample)
BR (1) BR112018007304A2 (enExample)
CA (1) CA3001599A1 (enExample)
CL (1) CL2018000927A1 (enExample)
EA (1) EA201890968A1 (enExample)
IL (2) IL311873A (enExample)
MX (2) MX394796B (enExample)
SG (1) SG10201912886XA (enExample)
WO (1) WO2017066599A1 (enExample)
ZA (1) ZA201802088B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170057411A (ko) 2014-09-29 2017-05-24 아지오스 파마슈티컬스 아이엔씨. 치료적 활성 화합물 및 이들의 사용 방법
WO2016126798A1 (en) 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA3002029A1 (en) 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
EP3509570A1 (en) 2016-09-07 2019-07-17 Celgene Corporation Tablet compositions
EP3618828B1 (en) 2017-05-05 2023-11-01 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
IL271946B (en) * 2017-07-09 2022-09-01 Biosight Ltd Combination cancer therapy
US10980788B2 (en) * 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
KR20220101148A (ko) 2019-11-14 2022-07-19 셀진 코포레이션 암의 치료를 위한 소아용 제제
CN111087408B (zh) * 2020-01-03 2021-04-02 浙江大学 一种大环结构的idh2突变体抑制剂及其医药用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ES2248908T7 (es) 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
ES2270982T3 (es) 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
JP6067226B2 (ja) 2009-03-13 2017-01-25 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞増殖関連疾患のための方法および組成物
CA2793836C (en) 2009-10-21 2020-03-24 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
KR101893112B1 (ko) 2012-01-06 2018-08-30 아지오스 파마슈티컬스 아이엔씨. 치료학적으로 활성인 화합물 및 이의 이용 방법
PE20160744A1 (es) 2013-07-11 2016-08-01 Agios Pharmaceuticals Inc Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer
TWI666208B (zh) 2013-08-02 2019-07-21 美商阿吉斯藥品有限公司 治療活性化合物及其使用方法（三）
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
KR20170057411A (ko) 2014-09-29 2017-05-24 아지오스 파마슈티컬스 아이엔씨. 치료적 활성 화합물 및 이들의 사용 방법
WO2016126798A1 (en) 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3331866B1 (en) 2015-08-05 2023-07-26 Les Laboratoires Servier Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine
CA3002029A1 (en) 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
CA3007363A1 (en) 2015-12-04 2017-06-08 Agios Pharmaceuticals, Inc. Methods of treatment of malignancies
US10137130B2 (en) 2016-02-26 2018-11-27 Celgene Corporation Methods of treatment of malignancies

Also Published As

Publication number Publication date
IL258269A (en) 2018-05-31
US20210386749A1 (en) 2021-12-16
EP3362057A1 (en) 2018-08-22
ZA201802088B (en) 2021-07-28
CL2018000927A1 (es) 2018-09-14
AU2016340087B2 (en) 2022-05-12
MX2022006701A (es) 2022-07-12
JP2021130682A (ja) 2021-09-09
MX2018004595A (es) 2019-07-04
US20180311249A1 (en) 2018-11-01
EP4147692A1 (en) 2023-03-15
NZ740792A (en) 2024-05-31
AU2016340087A1 (en) 2018-04-12
JP2018534288A (ja) 2018-11-22
BR112018007304A2 (pt) 2018-10-23
WO2017066599A1 (en) 2017-04-20
EA201890968A1 (ru) 2018-09-28
US10905692B2 (en) 2021-02-02
AU2016340087C1 (en) 2022-08-18
KR20250065944A (ko) 2025-05-13
MX394796B (es) 2025-03-24
CA3001599A1 (en) 2017-04-20
SG10201912886XA (en) 2020-02-27
CN108366980A (zh) 2018-08-03
KR20180063125A (ko) 2018-06-11

Similar Documents

Publication Publication Date Title
IL311873A (en) Combination therapy for treating malignancies
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
PH12016502168A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
MX2022001863A (es) Metodos para tratar los tumores del estroma gastrointestinal.
JOP20200130A1 (ar) مركبات كرومان مونوباكتام لعلاج العدوى البكتيرية
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
WO2017165822A8 (en) Small molecule inhibitor of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
EA200870454A1 (ru) Способ ингибирования c-kit киназы
WO2022023447A3 (en) Fused bicyclic raf inhibitors and methods for use thereof
EA200970536A1 (ru) Антибактериальные хинолиновые производные
MX2019000413A (es) Inhibidores de triptofano 2,3-dioxigenasa.
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2
MX2020008273A (es) Inhibidores de la cinasa del complejo de activacion transcripcional notch ("nack") y metodos para el uso de los mismos.
WO2019241641A3 (en) Cancer treatment methods
WO2020106751A8 (en) Inhibitors of gli1 as therapeutic agents